The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors
Open accessAbstract
Purpose: Pancreatic neuroendocrine tumors (PanNET) are a heterogeneous group of neoplasms with increasing incidence and unpredictable behavior. Whole-exome sequencing has identified recurrent mutations in the genes DAXX and ATRX, which correlate with loss of protein expression and alternative lengthening of telomeres (ALT). Both ALT and DAXX/ATRX loss were initially reported to be associated with a favorable prognosis; however, recent studies suggest the contrary. Our aims were to assess the prevalence and prognostic significance of ALT and DAXX/ATRX in both primary and metastatic PanNETs. Experimental Design: Telomere-specific FISH and DAXX/ATRX IHC was performed on a multi-institutional cohort of 321 patients with resected PanNET and 191 distant metastases from 52 patients. These results were correlated with clinicopathologic features, including disease-free survival (DFS) and disease-specific survival (DSS). Results: The prevalence of ALT and DAXX/ATRX loss in resected PanNETs was 31% and 26%, respectively, and associated with larger tumor size, higher WHO grade, lymph node metastasis, and distant metastasis (P < 0.001). The 5-year DFS and 10-year DSS of patients with ALT-positive and DAXX/ATRX-negative PanNETs were 40% and 50%, respectively, as compared with 96% and 89%, respectively, for wild-type PanNETs. Among distant metastases, ALT and DAXX/ATRX loss was 67% and 52%, respectively, and only occurred in the setting of an ALT-positive and DAXX/ATRX-negative primary PanNET. By multivariate analysis, both ALT and DAXX/ATRX loss were negative, independent prognostic factors for DFS. Conclusions: ALT and DAXX/ATRX loss in PanNETs was associated with shorter DFS and DSS and likely plays a significant role in driving metastatic disease. Clin Cancer Res; 23(2); 600–9. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gerdes, J., Lemke, H., Baisch, H., Wacker, H. H., Schwab, U., & Stein, H. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.133.4.1710 · Cited by 4,173
Altered Telomeres in Tumors with ATRX and DAXX Mutations
Heaphy, C. M., de Wilde, R. F., Jiao, Y., Klein, A. P., Edil, B. H., Shi, C., Bettegowda, C., Rodriguez, F. J., Eberhart, C. G., Hebbar, S., et al. (2011) · Science · doi:10.1126/science.1207313 · Cited by 1,083
Lovejoy, C. A., Li, W., Reisenweber, S., Thongthip, S., Bruno, J., de Lange, T., De, S., Petrini, J. H. J., Sung, P. A., Jasin, M., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002772 · Cited by 629
Heaphy, C. M., Subhawong, A. P., Hong, S.-M., Goggins, M. G., Montgomery, E. A., Gabrielson, E., Netto, G. J., Epstein, J. I., Lotan, T. L., Westra, W. H., et al. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.06.018 · Cited by 516
Histone variant H3.3 provides the heterochromatic H3 lysine 9 tri-methylation mark at telomeres
Udugama, M., Chang, F. T. M., Chan, F. L., Tang, M. C., Pickett, H. A., McGhie, J. D. R., Mayne, L., Collas, P., Mann, J. R., & Wong, L. H. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv847 · Cited by 109
Cited by
Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms
Rindi, G., Mete, O., Uccella, S., Basturk, O., La Rosa, S., Brosens, L. A. A., Ezzat, S., de Herder, W. W., Klimstra, D. S., Papotti, M., et al. (2022) · Endocrine Pathology · doi:10.1007/s12022-022-09708-2 · Cited by 1,036
Gastroenteropancreatic Neuroendocrine Tumors
Cives, M., & Strosberg, J. R. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21493 · Cited by 586
A mechanistic classification of clinical phenotypes in neuroblastoma
Ackermann, S., Cartolano, M., Hero, B., Welte, A., Kahlert, Y., Roderwieser, A., Bartenhagen, C., Walter, E., Gecht, J., Kerschke, L., et al. (2018) · Science · doi:10.1126/science.aat6768 · Cited by 335
Self-citationLawlor, R. T., Veronese, N., Pea, A., Nottegar, A., Smith, L., Pilati, C., Demurtas, J., Fassan, M., Cheng, L., & Luchini, C. (2019) · BMC Cancer · doi:10.1186/s12885-019-5424-8 · Cited by 62
von Arx, C., Capozzi, M., López-Jiménez, E., Ottaiano, A., Tatangelo, F., Di Mauro, A., Nasti, G., Tornesello, M. L., & Tafuto, S. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091277 · Cited by 24
Metadata
- Authors
- Singhi, A. D., Liu, T.-C., Roncaioli, J. L., Cao, D., Zeh, H. J., Zureikat, A. H., Tsung, A., Marsh, J. W., Lee, K. K., Hogg, M. E., Bahary, N., Brand, R. E., McGrath, K. M., Slivka, A., Cressman, K. L., Fuhrer, K., & O'Sullivan, R. J.
- Venue
- Clinical Cancer Research
- Published
- 2017-01-15
- Volume
- 23
- Issue
- 2
- Pages
- 600-609
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2468837258
- Cited by
- 250
- References
- 5
- FWCI
- 16.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-1113
- The paper
- Singhi, A. D., Liu, T.-C., Roncaioli, J. L., Cao, D., Zeh, H. J., Zureikat, A. H., Tsung, A., Marsh, J. W., Lee, K. K., Hogg, M. E., Bahary, N., Brand, R. E., McGrath, K. M., Slivka, A., Cressman, K. L., Fuhrer, K., & O'Sullivan, R. J. (2017). Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-1113
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.